| Literature DB >> 31430555 |
Paola Queirolo1, Andrea Boutros1, Enrica Tanda1, Francesco Spagnolo2, Pietro Quaglino3.
Abstract
Melanoma has always been described as an immunogenic tumor. Despite that, until 2011 the standard of care in metastatic melanoma was chemotherapy, with low response rates and no clear impact on overall survival. Melanoma was the first cancer type to drive the use of immune-checkpoint inhibitors into clinical practice, which revolutionized the therapeutic paradigm not only in melanoma, but also in an increasing number of tumors. In this review, the preclinical bases and the main clinical studies that led to the approval of immune-checkpoint inhibitors in advanced melanoma will be described with insights on novel combinations of treatments and on prognostic and predictive biomarkers.Entities:
Keywords: Biomarker; CTLA-4; Immune-checkpoint inhibitors; Immunotherapy; Melanoma; PD-1
Mesh：
Substances：
Year: 2019 PMID： 31430555 DOI： 10.1016/j.semcancer.2019.08.001
Source DB: PubMed Journal: Semin Cancer Biol ISSN： 1044-579X Impact factor: 15.707